A 2-year step-down withdrawal from inhaled corticosteroids in asthmatic children receiving immunotherapy

Background:Inhaled corticosteroids (ICSs) for treating asthma are controversial because of their negative effects on the growth of asthmatic children and without clearly defined withdrawal strategy.A 2-year ICS step-down and withdrawal strategy has been developed for asthmatic children receiving 3-year subcutaneous immunotherapy (SCIT).Methods:Eleven children were included into the SCIT group and 13 children into the ICS group.ICSs were discontinued when children met the following criteria:requiring only 1 puff per day,with good control,for at least 6 months;having a forced expiratory volume in 1 second (FEV1)/forced vital capacity ≥80%;and SCIT discontinued for ≥24 months.The main endpoints were the results of both the childhood asthma control test (C-CAT) and the methacholine bronchial provocation test.Results:In the SCIT group,all the 11 children had ICS discontinued,with one child developed asthma attack after pneumonia and received ICS again after completion of SCIT.In the ICS group,five children discontinued ICS and developed asthma attacks later and received ICS again;the other eight children developed severe symptoms during ICS step-down.Thus,the discontinuation of ICS was only achieved in the SCIT group.The dose of methacholine that caused a decrease of 20% in FEV1 continued to improve after discontinuation of ICS for the SCIT group and presented better results than the ICS group (P=-0.050).After completion of SCIT,the C-CAT had improved significantly after 30 months of treatment compared with the ICS group (P<0.05).Conclusion:In the present study,we developed a 2-year step-down and withdrawal strategy from ICSs strategy for allergic asthma children receiving SCIT;the strategy was efficacious and safe.